Figure 1.
Clinical response to VSTs. The patient was infused with donor-derived virus-specific T cells at a dose of 5 × 106 cells/m2 (dose level 1). Before receiving the cells, the patient had received rituximab twice. (a) The patient's EBV load over time, with arrows indicating the time points at which rituximab and T cells were administered. (b) Extensive disease on the PET–CT scan before SIRS and complete resolution on the follow-up scan 6 weeks later. EBV, Epstein-Barr virus; PET–CT, positron emission tomography–computed tomography; SIRS, systemic inflammatory response syndrome; VST, virus-specific T cells.